Zelnorm review

This drug has been removed from shelves, as requested by American Food and Drug Assosication. This medication has been known to cause heart attacks and strokes in certain patients. Zelnorm is designed as a short-term treatment for women with irritable bowel syndrome (IBS) and designed as a treatment for patients, under 65, with idiopathic constipation. Zelnorm is generically known as tegaserod maleate and acts as an agonist on the receptors in the GI tract to stimulate normal stools. Patients with irritable bowel syndrome (IBS) should be aware that Zelnorm is not a cure for the syndrome and that the therapy will usually last about 4 to 6 weeks. Patients with idiopathic constipation will note a reduction in straining, bloating and pain or discomfort in abdominal area. Once the therapy stops, symptoms may reoccur in one to two weeks.

Patients should take Zelnorm the exact way it was prescribed by the health care provider and the patient should take care to read the Information to Patient section that the pharmacy includes with the prescription. The use of Zelnorm should not be started if the patient is experiencing diarrhea. Usually the patient will be directed to the medication twice a day, on an empty stomach, shortly before meals. If a dose is missed, take the next scheduled dose should be taken, only if on an empty stomach. If the dose is close to the next scheduled dose, skip the missed dose and take the next schedule dose. Never take two doses at the same time or take additional doses in an attempt to compensate for missed doses. Caution is advisable if any additional over the counter medicines, herbal medicines or dietary supplements are taken while taking Zelnorm.

With a pregnancy rating of B, from the FDA, physicians should be cautious when prescribing Zelnorm to women who are pregnant or may become pregnant. It is undetermined whether this medication can be excreted while breast feeding. Zelnorm should not be prescribed to children because safety and efficacy has not been determined. Anyone who develops extreme diarrhea should stop the use of Zelnorm immediately. Any patient that develops symptoms of ischemic colitis (rectal bleeding, bloody diarrhea or new or worsening diarrhea) should stop treatment and should refrain from taking Zelnorm again.

There are not any severe interactions known with any other medications; however, it may reduce plasma concentrations of digoxin and oral contraceptives. There are several medical conditions that interact with Zelnorm. The prescribing physician should be aware if any patients have severe bowel problems such as ischemic colitis, gallbladder, liver or kidney problems. A thorough medical examination should be determined at the time of prescription.

Some patients may experience mild side effects which include gas, abdominal pain, headaches, dizziness, and migraines, and back or joint discomfort. These symptoms should be discussed with the prescribing physician but are not seen as urgent.

Patients who experience a sudden worsening of their abdominal pain should take it as a potential warning sign of serious complications and should report immediately to the nearest emergency room.

Allergic reactions (shown by swelling of the mouth, lips, tongue, or throat, hives, and difficulty breathing) are considered medical emergencies and should be treated as such.

Diarrhea, nausea, abdominal pain, vomiting and flatulence are all signs of overdose. If overdose occurs or is suspected, the patient should contact or go to their nearest emergency medical center or contact their local poison control center.

Zelnorm has the following structural formula:

Chemical structure of zelnorm

• Molecular formula of zelnorm is C16H23N5O
• Chemical IUPAC Name is 1-[[5-(hydroxymethyl)-1H-indol-3-yl]methylideneamino]-2-pentyl-guanidine
• Molecular weight is 301.387 g/mol
Zelnorm available : 6mg pills

Generic name: Tegaserod

Brand name(s): Zelmac

  Your Zelnorm review